
Novo’s Obesity Pipeline Keeps Evolving With up to $1B Lexicon Deal
In its search for its next-generation obesity drug, Novo Nordisk on Friday put $1 billion on the line for Lexicon Pharmaceuticals’ non-incretin obesity drug. Under the terms of the agreement, Novo will hand over up to $75 million in upfront and near-term …